2 weeks Ago By ABMN Staff
NovoCure Limited ( NASDAQ:NVCR – Get Free Report ) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company.
The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $25.50. A number of research analysts have weighed in on the company.
Wells Fargo & Company reduced their price target on NovoCure from $42.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th.
Evercore ISI increased their target price on NovoCure from $14.50 to $20.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 2nd.
Wedbush reaffirmed an “outperform” rating and issued a $24.00 target price on shares of NovoCure in a research report on Thursday, July 25th. Finally, HC Wainwright increased their target price on NovoCure from $22.
00 to $24.00 and gave the stock a “neutral” rating in a research report on Friday, July 26th. View Our Latest Research Report on NovoCure Hedge Funds Weigh In On NovoCure NovoCure Stock Down 0.
3 % NovoCure stock opened at $15.61 on Friday. NovoCure has a fifty-two week low of $10.
87 and a fifty-two week high of $24.74. The company has a debt-to-equity ratio of 1.
81, a quick ratio of 6.22 and a current ratio of 6.46.
The company has a market capitalization of $1.68 billion, a P/E ratio of -8.62 and a beta of 0.
71. The stock has a 50-day simple moving average of $18.36 and a 200-day simple moving average of $17.
59. NovoCure ( NASDAQ:NVCR – Get Free Report ) last released its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported ($0.
31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.09.
The business had revenue of $150.40 million for the quarter, compared to analysts’ expectations of $135.83 million.
NovoCure had a negative return on equity of 45.68% and a negative net margin of 30.67%.
The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.
54) EPS. Equities research analysts expect that NovoCure will post -1.34 earnings per share for the current year.
NovoCure Company Profile ( Get Free Report NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. Featured Articles Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.
com's FREE daily email newsletter ..
